FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283271310> ?p ?o ?g. }

• W4283271310 abstract "In 1988, Martin Rössle initiated and performed the first transjugular intrahepatic portosystemic shunt (TIPS) worldwide with implantation of a metallic Palmaz-stent in Freiburg, Germany, thus setting the stage for the establishment of a procedure that is now a standard interventional treatment for patients with various complications of portal hypertension and vascular diseases of the liver such as Budd-Chiari syndrome. In 2022, Martin Rössle received the inaugural EASL innovation award for this achievement that has revolutionized clinical practice in hepatology. Martin Rössle was born on August 11th in 1946 in Stuttgart, Germany, and grew up in a large family with 6 siblings including a twin sister. After his graduation from high school and 2 years of military service, he started to study both physics and medicine at the University of Freiburg in 1968. However, after a few years, his interest in medicine and biomedical research prevailed and he started his experimental doctoral thesis in 1971 in the Institute of Biochemistry under the supervision of Professor Karl Decker, a biochemist with a strong interest in hepatology, especially in galactosamine hepatitis and the role of Kupffer cells. In his doctoral thesis, Martin Rössle investigated the energy metabolism of Clostridium kluyveri and this work was awarded with the Gödecke research price. After successful completion of medical school, he first continued as a post-doc in the Institute of Professor Karl Decker before, in 1976, he started as a medical doctor in the Department of Gastroenterology and Hepatology under the mentorship of Professor Wolfgang Gerok, who was famous for his special focus on creating an inseparable link between clinic and science and applying basic scientific methods to clinically relevant problems. The research focus of Wolfgang Gerok was the biochemistry of bile secretion and regulation of amino acid and protein metabolism in the liver, where he closely interacted with Karl Decker, e.g. within a collaborative research center funded by the Deutsche Forschungsgemeinschaft (DFG). Thus, it was not surprising that Martin Rössle continued to perform his research in this field. Between 1985-1986, he performed a postdoctoral research fellowship at the National Institutes of Health, Bethesda, USA under the supervision of Dr. E. Anthony Jones and with support from DFG research grant. During his post-doc, he was working on GABA-benzodiazepine receptors in an animal model of acute hepatic encephalopathy and this clinically relevant work was published in Hepatology in 1989.[1]Rössle M. Deckert J. Jones E.A. Autoradiographic analysis of GABA-benzodiazepine receptors in an animal model of acute hepatic encephalopathy.Hepatology. 1989; 10: 143-147Crossref PubMed Scopus (21) Google Scholar However, after returning to Freiburg, he started to shift his attention to a new topic which would become the major focus of his research: portal hypertension. Importantly, he was strongly supported by his mentor Wolfgang Gerok who with his modest, empathic and interested personality created an atmosphere that fostered the initiation of this new avenue. In 1969, Joseph Rösch was the first to describe an interventional technique to establish TIPS in dogs. For this procedure, a silicone-coated spring coil was used that lasted for about 2 weeks. Palmaz introduced expandable metallic stents in 1985 that were successfully implanted in the cirrhotic livers of dogs.[2]Rössle M. TIPS: 25 years later.J Hepatol. 2013; 59: 1081-1093Abstract Full Text Full Text PDF PubMed Scopus (215) Google Scholar This inspired Martin Rössle and his team in Freiburg, who already had experience in hepatic vein catherization for transjugular liver biopsies, to perform this procedure in humans. Thus, as mentioned above, in 1988 and with the help of Julio C. Palmaz and the radiologist Götz Richter, the first TIPS procedures with implantation of a metallic Palmaz-stent were performed in Freiburg in 10 patients, notably, 120 years after Adolf Kussmaul had performed the first endoscopy worldwide at the University Hospital of Freiburg.[3]Rössle M. Richter G.M. Noeldge G. Siegerstetter V. Palmaz J.C. Wenz W. et al.The intrahepatic portosystemic shunt. Initial clinical experiences with patients with liver cirrhosis.Dtsch Med Wochenschr. 1989; 114: 1511-1516Crossref PubMed Scopus (28) Google Scholar,[4]Rössle M. Richter G.M. Noldge G. Palmaz J.C. Wenz W. Gerok W. New non-operative treatment for variceal haemorrhage.Lancet. 1989; 2: 153Abstract PubMed Scopus (65) Google Scholar TIPS implantation was technically successful in 7 patients, of whom 2 died early due to sepsis and bleeding, respectively. The TIPS procedures lasted an average of 8 hours and consisted of both, a transjugular and a percutaneous transcostal approach to place a metallic target (Dormia bascet) in the right branch of the portal vein. Due to these complications and technical difficulties, the TIPS program was temporarily stopped until Marc Perarnau from Metz, France, joined the group in Freiburg in 1990. He introduced an improved puncture technique including sonographic targeting of the portal vein. With this approach, the time of TIPS procedure could be reduced to the current 1-2 hours and the complication rate decreased significantly. Within 5 years, Rössle and his team performed 500 TIPS procedures in patients with cirrhosis and TIPS was established as a standard procedure.[2]Rössle M. TIPS: 25 years later.J Hepatol. 2013; 59: 1081-1093Abstract Full Text Full Text PDF PubMed Scopus (215) Google Scholar Indeed, within a few years, randomized controlled trials established TIPS as an effective therapy for patients with complications of cirrhosis, such as variceal bleeding and refractory ascites. Several of these landmark studies were published by Rössle and his team including his closest associates Drs. Klaus Haag and Andreas Ochs. For example, in 1994, Rössle et al. published a study in the NEJM showing that TIPS is an effective and safe treatment for variceal hemorrhage in patients with cirrhosis.[5]Rössle M. Haag K. Ochs A. Sellinger M. Noldge G. Perarnau J.M. et al.The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding.N Engl J Med. 1994; 330: 165-171Crossref PubMed Scopus (674) Google Scholar This was followed by a study in the Lancet showing that TIPS is more effective than endoscopic treatment in prevention of variceal rebleeding.[6]Rössle M. Deibert P. Haag K. Ochs A. Olschewski M. Siegerstetter V. et al.Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding.Lancet. 1997; 349: 1043-1049Abstract Full Text Full Text PDF PubMed Scopus (233) Google Scholar Rössle and his group also showed, in 2 studies published in 1998 and 2001 in the NEJM, that TIPS is an effective treatment for many patients with cirrhosis and refractory ascites, leading to a higher chance of survival compared to recurrent paracenteses.[7]Ochs A. Rössle M. Haag K. Hauenstein K.H. Deibert P. Siegerstetter V. et al.The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites.N Engl J Med. 1995; 332: 1192-1197Crossref PubMed Scopus (429) Google Scholar,[8]Rössle M. Ochs A. Gulberg V. Siegerstetter V. Holl J. Deibert P. et al.A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites.N Engl J Med. 2000; 342: 1701-1707Crossref PubMed Scopus (484) Google Scholar There is now clear evidence that TIPS should be strongly considered in patients with acute variceal bleeding, for secondary prophylaxis of rebleeding maybe combined with variceal embolization,[9]Schultheiss M. Giesler M. Maruschke L. Schmidt A. Sturm L. Thimme R. et al.Adjuvant transjugular variceal occlusion at creation of a transjugular intrahepatic portosystemic shunt (TIPS): efficacy and risks of bucrylate embolization.Cardiovasc Intervent Radiol. 2019; 42: 729-736Crossref PubMed Scopus (7) Google Scholar and in patients with hydrothorax and Budd-Chiari syndrome.[10]Blum U. Rössle M. Haag K. Ochs A. Blum H.E. Hauenstein K.H. et al.Budd-Chiari syndrome: technical, hemodynamic, and clinical results of treatment with transjugular intrahepatic portosystemic shunt.Radiology. 1995; 197: 805-811Crossref PubMed Scopus (141) Google Scholar Possible indications for TIPS that need to be discussed on an individual basis include cirrhotic and non-cirrhotic, non-malignant portal vein thrombosis and hepatorenal syndrome.[2]Rössle M. TIPS: 25 years later.J Hepatol. 2013; 59: 1081-1093Abstract Full Text Full Text PDF PubMed Scopus (215) Google Scholar Of course, TIPS also has complications, limitations and contraindications. Hepatic encephalopathy remains the major limitation of TIPS. Relative contraindications thus include pre-TIPS hepatic encephalopathy, bilirubin >3mg/dl, and older age. Cardiac disease and moderate to severe pulmonary hypertension are also regarded as contraindications for TIPS. The selection of patients and the definition of the best indications have been widely discussed, e.g. in the review article “TIPS: 25 years later” published by Martin Rössle in this journal.[2]Rössle M. TIPS: 25 years later.J Hepatol. 2013; 59: 1081-1093Abstract Full Text Full Text PDF PubMed Scopus (215) Google Scholar In 2001, Martin Rössle decided to leave the University Hospital Freiburg and founded a medical practice. However, he never left academia and remained associated with the University Hospital Freiburg to perform TIPS procedures. More importantly, he continued to perform scientific work and made major contributions, e.g. demonstrating the favorable long-term results associated with covered stents.[11]Rossle M. Siegerstetter V. Euringer W. Olschewski M. Kromeier J. Kurz K. et al.The use of a polytetrafluoroethylene-covered stent graft for transjugular intrahepatic portosystemic shunt (TIPS): long-term follow-up of 100 patients.Acta Radiol. 2006; 47: 660-666Crossref PubMed Scopus (69) Google Scholar Martin Rössle is a strong advocate for TIPS procedures being performed by hepatologists: “TIPS is not only a technical procedure, it requires a basic understanding of liver disease and all its complications and should therefore be performed by physicians directly involved in the care of the patients”. Thus, he continued to train hepatologists to perform TIPS procedures worldwide, including performing TIPS procedures in China or Indonesia. In recent years, he also intensified his collaborations with 2 young hepatologists, Dominik Bettinger and Michael Schultheiss, from the Department of Medicine II, University Hospital Freiburg, his alma mater. He not only taught them how to perform the TIPS procedure (“Let me show you how to do it, you do not need to make the same mistakes I have done years before”!) but also inspired, led or mentored several studies addressing the potential role of TIPS in patients with hepatocellular carcinoma,[12]Bettinger D. Knuppel E. Euringer W. Spangenberg H.C. Rössle M. Thimme R. et al.Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma.Aliment Pharmacol Ther. 2015; 41: 126-136Crossref PubMed Scopus (32) Google Scholar the rate of TIPS complications,[13]Bettinger D. Schultheiss M. Boettler T. Muljono M. Thimme R. Rössle M. Procedural and shunt-related complications and mortality of the transjugular intrahepatic portosystemic shunt (TIPSS).Aliment Pharmacol Ther. 2016; 44: 1051-1061Crossref PubMed Scopus (31) Google Scholar or comparing medical and interventional treatments in acute non-cirrhotic and non-malignant portal vein thrombosis.[14]Rössle M. Bettinger D. Trebicka J. Klinger C. Praktiknjo M. Sturm L. et al.A prospective, multicentre study in acute non-cirrhotic, non-malignant portal vein thrombosis: comparison of medical and interventional treatment.Aliment Pharmacol Ther. 2020; 52: 329-339Crossref PubMed Scopus (18) Google Scholar Most recently, he named a new and intensively discussed and already independently confirmed score developed by Dominik Bettinger and Michael Schultheiss for the optimal identification of high-risk patients who should be considered for TIPS implantation as the Freiburg index of post-transjugular intrahepatic portosystemic shunt survival score (FIPS).[15]Bettinger D. Sturm L. Pfaff L. Hahn F. Kloeckner R. Volkwein L. et al.Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.J Hepatol. 2021; 74: 1362-1372Abstract Full Text Full Text PDF PubMed Scopus (27) Google Scholar Martin Rössle has shaped the field of hepatology at the highest international level and to the benefit of generations of patients. In 2019, the German Association for the study of Liver Diseases (GASL) honoured Martin Rössle for his achievements with the Lucie-Bolte price. As Martin Rössle stated during this occasion, his achievements were only made possible by the continuous support, love and understanding of his family, his wife Johanna, his 2 children and his 5 stepchildren. Taken together, Martin Rössle has introduced TIPS as a standard procedure in the field of hepatology, has defined several of its indications/contraindications, has trained colleagues worldwide and is still scientifically active in teaching and addressing the important open questions. Clearly, the Inaugural EASL innovation award goes to the most appropriate person, well deserved. Congratulations!" @default.
• W4283271310 created "2022-06-23" @default.
• W4283271310 creator A5054826514 @default.
• W4283271310 date "2022-06-01" @default.
• W4283271310 modified "2023-10-16" @default.
• W4283271310 title "EASL innovation award recipient 2022: Prof. Martin Rössle" @default.
• W4283271310 cites W1525534239 @default.
• W4283271310 cites W1967535308 @default.
• W4283271310 cites W1983858940 @default.
• W4283271310 cites W2021084910 @default.
• W4283271310 cites W2049018790 @default.
• W4283271310 cites W2077621475 @default.
• W4283271310 cites W2111364952 @default.
• W4283271310 cites W2145452609 @default.
• W4283271310 cites W2314215304 @default.
• W4283271310 cites W2318484454 @default.
• W4283271310 cites W2526686602 @default.
• W4283271310 cites W2915494400 @default.
• W4283271310 cites W3033081888 @default.
• W4283271310 cites W3123540049 @default.
• W4283271310 cites W3144171032 @default.
• W4283271310 cites W4362208328 @default.
• W4283271310 doi "https://doi.org/10.1016/j.jhep.2022.05.025" @default.
• W4283271310 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35750547" @default.
• W4283271310 hasPublicationYear "2022" @default.
• W4283271310 type Work @default.
• W4283271310 citedByCount "0" @default.
• W4283271310 crossrefType "journal-article" @default.
• W4283271310 hasAuthorship W4283271310A5054826514 @default.
• W4283271310 hasConcept C41008148 @default.
• W4283271310 hasConceptScore W4283271310C41008148 @default.
• W4283271310 hasLocation W42832713101 @default.
• W4283271310 hasLocation W42832713102 @default.
• W4283271310 hasOpenAccess W4283271310 @default.
• W4283271310 hasPrimaryLocation W42832713101 @default.
• W4283271310 hasRelatedWork W1508817574 @default.
• W4283271310 hasRelatedWork W2002960094 @default.
• W4283271310 hasRelatedWork W2079751472 @default.
• W4283271310 hasRelatedWork W2131928396 @default.
• W4283271310 hasRelatedWork W2167581955 @default.
• W4283271310 hasRelatedWork W2368547358 @default.
• W4283271310 hasRelatedWork W2399308721 @default.
• W4283271310 hasRelatedWork W2918283945 @default.
• W4283271310 hasRelatedWork W3028827562 @default.
• W4283271310 hasRelatedWork W3141364327 @default.
• W4283271310 isParatext "false" @default.
• W4283271310 isRetracted "false" @default.
• W4283271310 workType "article" @default.